Endometrioid adenocarcinoma arising from abdominal wall endometriosis in the appendectomy scar: A case report

We report a very rare case of endometrioid adenocarcinoma arising from abdominal wall endometriosis in the appendectomy scar. A 47-year-old woman visited the surgical department, since she had a gradually growing and painful tumor both in an appendectomy scar and at an umbilical site. She underwent appendectomy at age 18 years, and noticed the tumor at age 22 years. Partial tumor resection was performed in that department, and the pathology revealed endometrioid adenocarcinoma. She was referred to our department for radical therapy. Tumors in the both sites were dissected together with some swelling lymph nodes in our department. A pathological diagnosis of the tumor in the umbilical site showed only benign endometriosis. In contrast, the tumor in the appendectomy scar showed benign endometriosis, atypical endometriosis and well differentiated endometrioid adenocarcinoma. Resected lymph nodes also contained endometrioid adenocarcinoma, and were diagnosed as metastases. It was concluded that the endometrioid adenocarcinoma in the tumor of the appendectomy scar was a malignant transformation arising from abdominal wall endometriosis from the pathological findings. Since the operation, adjuvant and maintenance chemotherapy with paclitaxel and carboplatin had been administered for 3 years. She is free of disease 3.5 years after the operation.

Adjuvant Chemotherapy versus Radiotherapy in High-risk,Early-stage Endometrioid Endometrial Carcinoma

Objective:The present study was designed to evaluate the effects of adjuvant chemotherapy(CT)vs.radiotherapy(RT,alone or combined with CT)on the prognosis of patients with high-risk,early-stage(stage I and stage II)endometrioid endometrial carcinoma.Methods:This single-center retrospective clinical study was conducted in Union Hospital,Tongji Medical College,Huazhong University of Science and Technology between 2010 and 2019.

Ovarian endometrioid carcinoma resembling sex cord-stromal tumor:A case report

BACKGROUND Ovarian endometrioid carcinoma resembling sex cord-stromal tumor(ECSCSs)is rare.CASE SUMMARY We present a rare case of primary ECSCSs in the left ovary.A 39-year-old female patient had persistent dull pain in the lower abdomen for more than 1 mo,and she was initially diagnosed with pelvic inflammatory disease at a hospital.The patient received transabdominal hysterectomy,bilateral salpingo-oophorectomy,and pelvic and para-aortic lymph node dissection at our hospital and finally diagnosed with ECSCSs.After the operation,the patient received eight courses of cisplatinum+etoposide+bleomycin chemotherapy treatment and no evidence of tumor recurrence or metastasis was found in a 2-year follow-up period.CONCLUSION Ovarian endometrioid carcinoma is similar to the ovary sex cord-stromal tumor,especially when the cord-like structure is obvious.The clinical diagnosis for this tumor is difficult before surgery and pathology examination.The necessary immunohistochemical markers are of positive significance for assisting diagnosis and differential diagnosis.

The Application of Quantum Dots Double-Labeling Immunofluorescence Technology in Detection of PR and CD146 in Paraffin-Embedded Tissue Sections of Endometrioid Adenocarcinoma

Objective: The aim was to detect the expression of PR and CD146 in paraf-fin-embedded tissue sections of endometrioid adenocarcinoma by using QDs double-labeling immunofluorescence, and evaluate the applied value of QDs double-labeling immunofluorescence in endometrioid adenocarcinoma. Methods: To detect the expression of PR and CD146 on 140 cases of paraffin-embedded tissue sections of endometrioid adenocarcinoma by using QDS double-labeling immunofluorescence. Results: The co-expression of PR and CD146 in the endometrioid adenocarcinoma can be detected by QDs double-labeling immunofluorescence, and there was no correlation between them (P > 0.05). Conclusion: QDs double-labeling immunofluorescence can detect the localization and co-expression of PR and CD146 in the endometrioid adenocarcinoma.

OVEREXPRESSION OF p53, EGFR,C-ERBB2 AND C-ERBB3 IN ENDOMETRIOIDCARCINOMA OF THE OVARY

Objectives. To determine overexpression of p53, EGFR, e-erbD-2 and e-erbB-3 in endometrioid carcinoma of the ovary and to evaluate the prognostic signiFtcance of these resdts, especially, eoexlsting overexpression of p53 and one of the member of type I growth factor receptor family. Methods. Overexpressions of the p53, EGFR, e-erbB-2 and e-erbB-3 protein were studied by immunohlstochemistry in paraffin-embedded tumor tissue from 28 patients with endometrioid carcinoma of the ovary. Results. 11 (39.3%), 13 (46.4%), and 14 (50. 0%) were stained positively with p53, e-erbB-2 and c-erbB-3 monoclonal ant/bodies. 13 (46. 4%) was stained positively with EGFR polyclonal antibody.There were no relationship between p53, EGFR, C-erbB-2, c-erbB-3 and histologic grade, lymph node metastasis. The percentage of tumors with over expression of p53, EGFR, C-erbB-2 and c-erbB-3 was higher in those with stage Ⅰ～Ⅱ tumors compared with those with stage Ⅰ, in patients with residual tumor after initial surgery compared with those without. A high survival rate was observed in patients without p53, EGFR, c-erbB-2 and c-erbB-3 overexpression respectively than those with. A highest survival rate was observed in patients with both p53 and one of EGFR, c-erbB-2 and c-erbB-3 negative compared with those both positive or either of both positive. Concltrsion. Overexpression of p53, EGFR, c-erbB-2 and C-erbB-3 resulted in a poorer prognosis respectively. Overexpression of both p53 and one of the EGFR, c-erbB-2 and e-erbB-3 is a worse prognostic indicator in patients with endometrioid carcinoma of the ovary.

超声引导介入治疗卵巢子宫内膜样囊肿患者疗效及血清肿瘤标志物水平的研究

目的:探究超声引导介入治疗卵巢子宫内膜样囊肿患者的疗效及血清肿瘤标记物水平。方法:将本院2019年5月至2022年5月收治的80例卵巢子宫内膜样囊肿患者随机分为两组。对照组40例行腹腔镜囊肿剔除术,研究组40例行超声引导介入穿刺治疗。比较两组的临床疗效、手术时间、抗生素使用时间及住院时间;评价两组手术前后的血清肿瘤标志物水平及卵巢功能指标变化,观察两组术后1年的复发率。结果:研究组的临床疗效高于对照组(P<0.05);研究组的手术时间、抗生素使用时间及住院时间短于对照组(P<0.05);术后6个月,研究组的血清糖类抗原125(CA125)、糖类抗原199(CA199)、人附睾蛋白4(HE4)水平均低于对照组(P<0.05);术后6个月,研究组的雌激素(E2)水平低于对照组,卵泡刺激素(FSH)、黄体生成素(LH)水平高于对照组(P<0.05);研究组术后1年的复发率低于对照组(P<0.05)。结论:对卵巢子宫内膜样囊肿患者应用超声引导介入穿刺治疗可增强疗效,降低血清肿瘤标记物水平,改善卵巢功能,降低术后复发率。

子宫内膜样癌中KIFC1的表达及临床意义

目的探讨驱动蛋白家族成员C1(KIFC1)在子宫内膜样癌中的表达与其临床病理特征和患者预后的相关性。方法采用免疫组化SP法检测30例癌旁正常子宫内膜组织和95例子宫内膜样癌组织中KIFC1的表达;应用qRT-PCR和Western blot法检测30对新鲜癌组织和相邻非癌组织中KIFC1 mRNA和蛋白表达;利用TCGA数据库分析KIFC1的表达与子宫内膜样癌患者生存期的关系;分析其临床病理特征并复习相关文献。结果KIFC1在子宫内膜样癌组织中的阳性率(61.05%)显著高于癌旁正常子宫内膜组织(13.33%),差异有统计学意义(P<0.05);KIFC1表达与子宫内膜样癌肌层浸润深度、FIGO分期和淋巴结转移均相关(P均<0.05)。qRT-PCR结果显示,子宫内膜样癌中KIFC1 mRNA相对表达量(2.99±0.59)显著高于癌旁正常子宫内膜组织(1.00±0.29,P<0.05)。Western blot结果显示,子宫内膜样癌中KIFC1蛋白相对表达量(1.70±0.36)显著高于癌旁正常子宫内膜组织(0.72±0.17,P<0.05)。生存分析发现,子宫内膜样癌中KIFC1阳性患者生存期明显低于阴性患者(P<0.05)。结论KIFC1在子宫内膜样癌中表达上调与患者不良预后相关,提示其可能成为子宫内膜样癌潜在的治疗靶点和预后评估指标。

卵巢浆黏液性肿瘤7例临床病理分析及分子特征

目的探讨卵巢浆黏液性肿瘤的临床病理特征、免疫表型、鉴别诊断及分子特征。方法收集7例卵巢浆黏液性肿瘤的临床病理资料,进行病理形态观察、免疫组织化学及分子检测,并复习文献。结果7例患者年龄25~56岁,中位年龄42岁,肿瘤最大径2.8~13.0 cm,1例双侧,6例单侧。7例均由颈管内膜型黏液上皮及苗勒管上皮组成,形成乳头状、筛状及微乳头状结构,伴大量中性粒细胞浸润,毁损性浸润及细胞异型显著提示恶变。免疫组化:7例表达雌激素受体、孕激素受体、细胞角蛋白7;5例表达PAX-8;3例表达PAX-2;7例PTEN缺失;Ki-67增殖指数为5%~40%;2例BRAF、PIK3CA、PIK3R1、PTEN基因突变,ARID1A、Tp53、BRCA1、BRCA2未见异常。7例均微卫星稳定。结论卵巢浆黏液性肿瘤有独特的病理形态学特征。免疫表型及分子特征提示其与子宫内膜样肿瘤重叠,预后较好。

Molecular subtypes identified by gene expression profiling in early stage endometrioid endometrial adenocarcinoma

Background Early stage （FIGO stage Ⅰ-Ⅱ） endometrioid endometrial adenocarcinoma （EEA） is very common in clinical practice.However,patients with the early stage EEA show various clinical behaviors due to biological heterogeneity.Hence,we aimed to discover distinct classes of tumors based on gene expression profiling,and analyze whether the molecular classification correlated with the histopathological stages or other clinical parameters.Methods Hierarchical clustering was performed for class discovery in 28 eady stage EEA samples using a special cDNA microarray chip containing 492 genes designed for endometrial cancer.Correlations between clinicopathologic parameters and our classification were analyzed.And the significance analysis of microarrays （SAM） array was used to identify the signature genes according to the tumor grade and myometrial invasion.Results Three tumor subtypes （subtypes Ⅰ,Ⅱ and Ⅲ） were identified by hierarchical clustering,each subtype had different clinicopathological factors,such as tumor grade,myometrial invasion status,and FIGO stage.Moreover,SAM analysis showed 34 up-regulated genes in high grade tumors,and 38 up-regulated genes and 1 down-regulated in deep myometrial invasive tumors.The overlap genes between these two high-risk factors were markedly up-regulated in subtype Ⅰ,but down-regulated in subtype Ⅲ.Conclusion We have identified novel molecular subtypes in early stage EEA.Differential gene signatures characterize each tumor subtype,which could be used for recognizing the tumor risk and providing a basis for further treatment stratification.

Hsa_circ_0007067在子宫内膜样癌中的表达及临床意义

目的:子宫内膜癌是女性生殖系统常见的恶性肿瘤,以子宫内膜样癌(endometrioid adenocarcinoma,EEC)最常见,其发病机制目前尚不清楚,已有研究证明环状RNA(circular RNA,circRNA)的表达与EEC的进展有关。本研究旨在检测hsa_circ_0007067在EEC中的表达,并探讨Hsa_circ_0007067与EEC临床病理特征的关系。方法:应用高通量测序分析2例EEC组织和2例正常子宫内膜组织基因表达水平,以|log2(Fold changes)|≥1.5且P<0.05为筛选标准,选择下调最显著的hsa_circ_0007067为研究对象,应用实时聚合酶链反应(real-time PCR)检测36例EEC组织(EEC组)和36例正常子宫内膜组织(对照组)中hsa_circ_0007067的相对表达量。生物信息学分析预测hsa_circ_0007067的结合位点和编码能力。结果:EEC组中hsa_circ_0007067表达水平显著低于对照组(P<0.05),且表达水平与国际妇产科联盟(Inter-national Federation of Gynecology and Obstetrics,FIGO)分期和组织分化程度有关;受试者操作特征(receiver operating characteristic,ROC)曲线显示曲线下面积(area under curve,AUC)为0.936,敏感度为0.833,特异度为0.889,最佳截断值为0.722,差异具有统计学意义(P<0.05)。Hsa_circ_0007067具有翻译成多肽的潜能,circbank数据库预测其miRNA潜在结合位点共24个。结论:Hsa_circ_0007067与EEC的发生、发展相关,可能通过与下游靶基因miRNA结合或编码蛋白质功能影响EEC的进程,有望作为EEC早期筛查和判断预后的分子指标。

子宫内膜样腺癌组织NuSAP1、MFN2表达与临床病理特征和预后的关系

目的探讨子宫内膜样腺癌(EA)组织核仁纺锤体相关蛋白1(NuSAP1)、线粒体融合蛋白2(MFN2)表达与临床病理特征和预后的关系。方法选取2019年3月至2020年10月南阳市第一人民医院收治的121例EA患者作为研究对象,应用免疫组织化学染色法检测患者癌组织及其对应癌旁组织NuSAP1、MFN2阳性表达率,分析癌组织NuSAP1、MFN2阳性表达率与患者临床病理特征的关系。出院后随访3年,完成随访112例,应用Kaplan-Meier生存曲线分析NuSAP1、MFN2阳性表达组和阴性表达组的预后差异,应用多因素COX回归分析EA患者预后的影响因素。结果EA癌组织NuSAP1阳性表达率为72.37%,明显高于癌旁组织的35.54%,MFN2阳性表达率为38.02%,明显低于癌旁组织的80.17%,差异均有统计学意义(P<0.05);国际妇产科联盟(FIGO)临床分期Ⅱ~Ⅲ期、中低分化、有淋巴结转移、深肌层浸润癌组织中NuSAP1阳性表达率分别为88.68%、83.54%、96.15%、90.63%,明显高于FIGO临床分期Ⅰ期的60.29%、高分化的57.14%、无淋巴结转移的55.79%、浅肌层浸润癌组织的66.29%,差异均有统计学意义(P<0.05);FIGO临床分期Ⅱ~Ⅲ期、中低分化、有淋巴结转移、深肌层浸润癌组织中MFN2阳性表达率分别为18.87%、30.38%、7.69%、15.63%,明显低于FIGO临床分期Ⅰ期的52.94%、高分化的52.38%、无淋巴结转移的46.32%、浅肌层浸润癌组织的46.07%,差异均有统计学意义(P<0.05);Kaplan-Meier法分析结果显示,NuSAP1阴性表达组和MFN2阳性表达组患者的3年生存率分别为90.00%和87.80%,明显高于NuSAP1阳性表达组的69.51%和MFN2阴性表达组的67.61%,差异均有统计学意义(P<0.05)。结论EA患者组织中NuSAP1阳性表达率升高,MFN2阳性表达率降低,NuSAP1、MFN2表达水平与患者肿瘤分化、FIGO临床分期、淋巴结转移及深肌层浸润有关,且是患者死亡的危险因素,提示NuSAP1、MFN2可能参与了EA患者的疾病进展。

盆腔和低位腹主动脉旁淋巴结清扫对国际妇产科联盟分期Ⅰ期子宫内膜样癌患者的安全性和预后的影响

目的探讨盆腔和低位腹主动脉旁淋巴结清扫术对国际妇产科联盟(FIGO)分期Ⅰ期子宫内膜样癌患者疗效及预后的影响。方法回顾性分析2018年1月至2020年1月中国人民解放军联勤保障部队第910医院收治的81例接受手术治疗的早期子宫内膜样癌患者的临床资料。根据患者淋巴结清扫方法不同分为盆腔淋巴结清扫(PLD)组(n=44)和低位腹主动脉旁淋巴结清扫(PALD)+PLD组(n=37)。比较两组的手术相关资料、术后1年复发率、3年总生存率及并发症发生情况。结果PALD+PLD组的手术时间显著长于PLD组,淋巴结清扫数和阳性淋巴结数显著大于PLD组(P<0.05)。两组术中、术后并发症发生率比较,差异无统计学意义(P>0.05)。两组1年内复发率比较,差异具有统计学意义(P<0.05)。两组3年总生存率比较,差异无统计学意义(P>0.05)。结论盆腔和低位腹主动脉旁淋巴结清扫术可降低FIGO分期Ⅰ期子宫内样膜癌患者的复发率,且不会提高手术并发症发生率。

MMR、PD-L1在子宫内膜样癌中的表达及其与预后的相关性

目的探讨错配修复蛋白(MMR)、程序性死亡配体-1(PD-L1)在子宫内膜样癌(EEC)中的表达及其与预后的关系。方法收集2015年1月-2020年9月潍坊市人民医院病理科诊断的EEC组织标本90例、子宫内膜不典型增生组织30例、子宫内膜样癌旁组织30例及子宫内膜不典型增生旁组织10例,对不同子宫内膜组织中的MMR、PD-L1表达情况采用免疫组化法进行检测,分析MMR、PD-L1表达与患者临床病理特征关系及与预后的相关性。结果MMR缺失(dMMR)、PD-L1在EEC组织中表达高于不典型增生组织、子宫内膜不典型增生旁组织及EEC旁组织(检验水准<0.017);dMMR、PD-L1与EEC的年龄及淋巴结转移、FIGO分期、肌层浸润深度无关(P>0.05);PD-L1的表达在G3期较G1期表达上调(检验水准<0.017);PD-L1与dMMR呈正相关(P<0.05);dMMR、PD-L1与患者预后有关,dMMR、PD-L1阳性的患者预后更差,MMR可以作为影响EEC患者生存的独立因素(P<0.05)。结论dMMR、PD-L1在EEC发生发展过程中起协同作用。dMMR、PD-L1与患者预后有关。dMMR是影响EEC预后的独立因素,联合检测MMR、PD-L1可能为EEC预后评估提供理论依据。

Dual-specificity Phosphatase 1 Deficiency Induces Endometrioid Adenocarcinoma Progression via Activation of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Pathway

Background： Previously, we reported that dual-specificity adenocarcinoma （EEA）. However, the role of DUSP1 medroxyprogesterone （MPA） are still unclear. phosphatase I （DUSPI） was differentially expressed in endometrioid in EEA progression and the relationship between DUSPI and Methods： The expression of DUSPI in EEA specimens was detected by immunohistochemical analysis. The effect of DUSPI on cell proliferation was analyzed by Cell Counting Kit 8 and colony formation assay, and cell migration was analyzed by transwell assay. MPA-induced DUSPI expression in EEA cells was measured by Western blot. Results： DUSPI expression was deficient in advanced International Federation of Gynecology and Obstetrics stage, high-grade and myometrial invasive EEA. In EEA cell lines （HeclA, Hecl B, RL952, and Ishikawa）, the DUSP1 expression was substantially higher in lshikawa cells than in other cell lines （P 〈 0.05）. Knockdown ofDUSP I promoted lshikawa cells proliferation, migration, and activation of mitogen-activated protein kinases/extracellular signal-regulated kinase （MAPK/Erk） pathway. MPA-induced DUSP1 expression and inhibited MAPK/Erk pathway in Ishikawa cells. Conclusions： Our data suggest that DUSP1 deficiency promotes EEA progression via MAPK/Erk pathway, which may be reversed by MPA, suggesting that DUSP I may serve as a potential therapeutic target for the treatment of EEA.

微小RNA-181c-5p和Kruppel样因子6在子宫内膜样腺癌组织中的表达及其与患者临床病理特征关系研究

目的:检测子宫内膜样腺癌组织中微小RNA-181c-5p(miR-181c-5p)和Kruppel样因子6(KLF6)的表达,探讨其相关性及临床意义。方法:选择49例子宫内膜样腺癌行手术治疗的患者作为观察组,选择49例增生期子宫内膜组织作为对照组。应用实时荧光定量PCR法检测术后组织中miR-181c-5p的表达,应用免疫组化方法检测KLF6的表达。应用线性相关分析观察miR-181c-5p和KLF6的关系,应用K-M生存分析观察miR-181c-5p和KLF6与术后生存时间的关系。结果:观察组miR-181c-5p表达量明显低于对照组(P<0.05),KLF6的阳性率明显低于对照组(P<0.05)。观察组miR-181c-5p与KLF6表达与肿瘤肌层浸润深度、宫颈管累犯及病理分级密切相关(均P<0.05),且两者具有正相关性,两者的表达与术后生存时间相关(均P<0.05)。结论:子宫内膜样腺癌中miR-181c-5p和KLF6均异常表达且具有正相关性,联合检测miR-181c-5p和KLF6的表达对判断肿瘤预后可能有一定价值。

卵巢子宫内膜样腺纤维瘤1例

目的探讨卵巢子宫内膜样腺纤维瘤的影像特点,以提高对该疾病的认识。方法回顾性分析1例经病理证实的卵巢子宫内膜样腺纤维瘤的影像表现,并复习相关文献。结果超声检查可见盆腔囊实性肿物,囊性回声内可见分隔,彩色多普勒成像(CDFI)显示实性部分有血流信号。CT可见盆腔内混杂密度肿物,病灶中间密度不均,增强扫描呈不均匀强化,病变两侧密度均匀,增强扫描无强化。MRI可见子宫后壁增厚,可见多发散在小囊状T_(2)WI高信号,两侧附件区可见多发囊实性肿物;囊性部分于T_(1)WI上呈高/稍高信号,T_(2)WI上呈低/高信号,实性部分于T_(1)WI上呈稍低信号,T_(2)WI上呈高信号;增强扫描显示实性部分呈中度不均匀强化,囊性部分无强化,实性部分内见间隔样结构,于T_(1)WI呈低信号,T_(2)WI呈低信号,增强扫描呈渐进样强化。结论卵巢子宫内膜样腺纤维瘤影像表现具有一定的特征,对其充分认识有助于准确诊断。

卵巢子宫内膜样癌的超声诊断价值

目的:观察卵巢子宫内膜样癌的超声表现,总结超声图像特点,提高术前对此病的诊断水平。方法:收集2021年1月至2022年12月于浙江大学医学院附属妇产科医院就诊,经手术病理证实的21例卵巢子宫内膜样癌患者完整的临床资料。结果:21例患者中,单侧患病18例,双侧患病3例。本研究中卵巢子宫内膜样癌的主要超声表现为实性低回声包块或囊实性混合回声包块。其中同时伴有子宫内膜病变患者11例,伴有或具有内异囊肿病史者9例,伴有腹水患者4例。结论:卵巢子宫内膜样癌超声表现具有一定特点,结合临床症状、血清CA125水平以及内膜病变或内异囊肿病史,可以一定程度上提高本病的术前诊断。

伴MELF生长方式的子宫内膜样癌临床病理特征及免疫表型的研究

目的探讨伴微囊性、伸长、碎片状(MELF)生长方式的子宫内膜样癌的临床病理特征及免疫表型特点。方法收集2013年9月—2019年1月新疆巴州人民医院行子宫全切除+双侧附件切除+盆腔淋巴清扫术的72例子宫内膜样癌患者的临床病理资料,判定MELF浸润情况,调查患者的一般资料、临床病理特点、免疫组化染色结果并进行比较分析,随访患者的预后情况。结果在72例患者中,病理诊断为伴MELF生长方式的子宫内膜样癌(伴MELF浸润组)占16.7%(12/72);不伴MELF生长方式的子宫内膜样癌(不伴MELF浸润组)占83.3%(60/72)。不伴MELF浸润组的年龄、绝经状态比较,差异有统计学意义(P<0.05)。伴MELF浸润组的病理分级、淋巴脉管间质浸润、淋巴结转移等与不伴MELF浸润组比较,差异有统计学意义(P<0.05)。伴MELF浸润组中,ER、PR、Ki-67、P16、CK阳性表达率分别为8.3%、16.7%、91.6%、100.0%、100.0%。不伴MELF浸润组中,ER、PR、Ki-67、P16、CK呈棕黄色强阳性表达,阳性表达率均为100.0%。随访期内患者均无肿瘤转移与肿瘤复发情况发生。结论MELF浸润在子宫内膜样癌中比较常见,伴MELF生长方式的子宫内膜样癌ER与PR表达阳性率显著降低,淋巴结转移阳性率、LVSI阳性率明显增高。

卵巢子宫内膜样癌与高级别浆液性癌的MRI鉴别诊断

目的:比较卵巢子宫内膜样癌(OEC)与高级别浆液性癌(HGSC)的MRI特征,为两者的术前鉴别诊断提供依据。方法:回顾性选取2017年1月—2023年11月来宾市人民医院收治的24例OEC和49例HGSC患者,术前已行MRI影像检查并经临床手术病理证实,比较其临床特征及MRI特征并总结分析。结果:2种癌症的肿瘤标志物水平、有无贫血、肿瘤最大径差异均无统计学意义(P>0.05);而2种癌症的患者发病年龄、FIGO分期、单双侧发病、边界、实性部分最大径、肿瘤囊实性分布特点、囊性T_(1)WI信号、实性部分强化特点、实性成分DWI高b值信号特点、大量腹水发生率、淋巴结转移及腹膜种植转移、合并子宫内膜病变,差异均有统计学意义(P<0.05)。结论:OEC典型表现为大单囊伴“梳妆”乳头样偏心附壁肿块为主、囊内伴或不伴纤维分隔;HGSC表现以实性占比为主的多房囊实性肿块伴多发纤维分隔并可能双侧癌。

卵巢子宫内膜样癌与高级别浆液性癌临床及MRI特征的对照分析

目的:探讨卵巢子宫内膜样癌(OEC)与高级别浆液性癌(HGSC)的临床及MRI特征表现,评价MRI对OEC与HGSC的鉴别诊断价值。方法:回顾性分析经手术病理证实的12例OEC患者(OEC组)及22例HGSC患者(HGSC组)的临床资料及MRI特征表现。临床资料包括患者年龄、体征、绝经状态、实验室检查、有无合并子宫内膜异位症等。MRI特征表现包括肿瘤形态、偏侧性、壁结节形态、囊性灶多寡特点、囊性成分信号特征、实性成分强化方式、肿瘤有无包膜、双发癌灶(合并子宫内膜癌)、腹膜种植、淋巴结转移及腹水情况等。结果:OEC与HGSC在肿瘤偏侧性、囊性灶多寡特点、部分囊性成分T1WI高信号、壁结节形态、双发癌及腹膜种植转移的组间差异均有统计学意义(均P<0.05)。相较于HGSC,OEC形态较规则,大多单侧发病,单囊为主,部分囊性成分T1WI高信号,壁结节较光滑,双发癌相对多见,腹膜种植转移相对少。结论:OEC与HGSC的病灶偏侧性、囊性灶多寡特点、部分囊性成分T1WI高信号、壁结节形态及双发癌等MRI特征表现存在差异,有助于两者的鉴别诊断。